New drugs help sparkling Pfizer results; company raises 2016 forecasts

Global company sales jumped 20 percent to $13 billion, which was $1 billion more than Wall Street had expected. Pfizer said sales would be hurt in the fourth quarter of 2016, however, when those added days will be offset by fewer days. Credit Suisse analyst Vamil Divan said the results were impressive, with most drug categories beating sales expectations.